AbbVie Inc. (ABBV) vs Halozyme Therapeutics, Inc. (HALO)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| ABBV | HALO | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Size band | MEGA | LARGE |
| Listing | NYSE | Nasdaq GS |
| Country | United States | United States |
| Theme | pharmaceuticals-large-cap | contract-research-cdmo |
| Price and returns | ||
| Last close | $286.74 | $128.01 |
| Return · 1 week | +1.44% | +4.50% |
| Return · 1 month | +7.68% | +13.39% |
| Return · 3 months | +8.94% | +53.40% |
| Return · year to date | +27.10% | +82.07% |
| Return · 1 year | +27.81% | +94.40% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −1.60% | −0.08% |
| 52-week high | $291.40 | $128.11 |
| 52-week low | $190.75 | $61.23 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $506.70B | $14.53B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $1.26B | $246.39M |
| Employees | 57,000 | 423 |
| Valuation | ||
| Price to earnings · trailing | 78.10× | 36.73× |
| Price to earnings · forward | 17.00× | 11.76× |
| Price to sales | 7.59× | 8.57× |
| Price to book | n/a (negative book value) | 99.79× |
| Enterprise value to EBITDA | 17.68× | 15.42× |
| Enterprise value to revenue | 8.45× | 9.74× |
| PEG ratio | 0.55 | — |
| Earnings per share · trailing | 3.54 | 3.42 |
| Profitability | ||
| Gross margin | 71.48% | 82.42% |
| Operating margin | 40.04% | 59.80% |
| Profit margin | 9.74% | 24.86% |
| Return on equity | — | 173.67% |
| Return on assets | 10.51% | 25.49% |
| Growth | ||
| Revenue growth | +10.20% | +47.70% |
| Earnings growth | +290.40% | +42.90% |
| Balance sheet and payout | ||
| Debt / equity (%) | — | 1,517.69 |
| Current ratio | 0.81 | 2.71 |
| Dividend yield | 2.55% | 0.00% |
| Payout ratio | 190.40% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 66.15 | 76.58 |
| ADX · 14 | 34.31 | 32.02 |
| 50-day average | $266.87 | $111.72 |
| 200-day average | $235.72 | $82.22 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.44% | 2.75% |
The full ABBV analysis
Everything this table leaves out for AbbVie Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ABBV argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ABBV analysisThe full HALO analysis
Everything this table leaves out for Halozyme Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the HALO argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full HALO analysis